Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease
RCT
OA: closed
CC0
⤵ 20 in-corpus citations
AI-generated summary
This controlled trial investigated the efficacy of the antigonadotropin danazol in treating painful nodular benign breast disease.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
In a double-blind crossover study of the effects of the antigonadotropin danazol on pain and nodularity in 28 women with cyclical mastalgia danazol was given at doses of 200 mg/day and 400 mg/day, and the responses were assessed both subjectively and objectively. Danazol caused a significant and progressive decrease in breast pain and nodularity when compared with placebo. Symptoms responded more quickly with the 400 mg/day dose of danazol than with the 200 mg dose, but the larger dose also caused greater side-effects. Danazol is a useful addition to the range of antihormones that can be used to suppress the symptoms of severe hormone-related benign breast disease.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (17)
- Clinical studies with an antigonadotropin-Danazol via openalex
- Clinical trial of danazol for benign breast disease via openalex
- Danazol for benign breast disease via openalex
- Danazol treatment of chronic cystic mastopathy: a clinical and hormonal evaluation via openalex
- The effect of danazol in the treatment of chronic cystic mastitis via openalex
- The treatment of benign breast disease with danazol via openalex
- The use of an impeded androgen--danazol--in the management of benign breast disorders via openalex
- The use of danazol in the treatment of painful benign breast disease: preliminary results via openalex
- Treatment of benign breast disease with danazol: a follow-up report via openalex
- Treatment of severe cyclical mastalgia via openalex
- W6714270639 via openalex
- doi:10.1136/bmj.1.4608.750 via openalex
- doi:10.1177/003591576906201005 via openalex
- doi:10.1136/bmj.281.6253.1450 via openalex
- doi:10.1016/s0140-6736(76)92477-6 via openalex
- W6633416704 via openalex
- doi:10.1002/bjs.1800651015 via openalex
Cited by (18)
- A Comparative Study of Danazol alone with Danazol Combined with Evening Primrose Oil in the Treatment of Fibrocystic Breast Disease 2022
- Evidence-based management of Mastalgia: a meta-analysis of randomised trials 2007
- Evaluation and management of breast pain 2004
- Benign breast disease 2001
- Gestrinone in mastalgia: A randomized double blind placebo controlled trial 1994
- Multicentre study of gestrinone in cyclical breast pain 1992
- Progesterone receptor induction by danazol in cultured cancer cells and the rat uterus 1992
- Mastalgia refractory to drug treatment 1990
- Management of breast pain and nodularity 1989
- The treatment of symptomatic benign breast disease with danazol 1988
- Cyclical mastopathy: a critical review of therapy 1988
- Reduction of Cysts in Fibrocystic Breast Disease during and after Danazol Treatment 1986
- Treatment of cyclical mastalgia with low dose short term danazol 1986
- Clinical experience of drug treatments for mastalgia 1985
- Endocrine effects of danazol in the treatment of endometriosis 1984
- Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double-blind placebo-controlled study--the Hjørring project 1984
- Danazol treatment of severely symptomatic fibrocystic breast disease and long-term follow-up--the Hjørring project 1984
- Vitamin D metabolites and analogues, diphosphonates, danazol, and bromocriptine 1983
Source provenance
- openalex
- last seen: 2026-05-10T10:18:44.795447+00:00
- pubmed
- last seen: 2026-10-08T21:58:02.984372+00:00
- unpaywall
- last seen: 2026-10-17T06:24:38.187582+00:00
License: CC0
· commercial use OK